Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:GBR Directive 2001/20/EC 04-Apr-2001 Article 2 (a)

From GxPlex

Revision as of 20:43, 27 June 2026 by Gxplex admin (talk | contribs) (1 revision imported)
Jump to: navigation, search


Document Information

Document information
Reference GBR Directive 2001/20/EC 04-Apr-2001
Validity area GBR
Scope(s) HM
Document name Directive 2001/20/EC
Version / Revision 04-Apr-2001
Status Current
Document type Legal act
Language(s) EN
Description DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL - of 4 April 2001

on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use

The European Directive (2001/20/EC) no longer applies in the UK. The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations amend the Medicines for Human Use (Clinical Trials) Regulations 2004 to enable the MHRA to operate as a regulator outside the EU.

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details

Scope HM
Document part Article 2 (a)
Language EN
Original entry by Florian Adragna
Contributors
Tags (EN)
Tags (original language)
Tags (FR)
Comment Definitions applicable to this directive (clinical trial, non-interventional)

Text

Definitions For the purposes of this Directive the following definitions shall apply:

(a)‘clinical trial’: any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of one or more investigational medicinal product(s), and/or to identify any adverse reactions to one or more investigational medicinal product(s) and/or to study absorption, distribution, metabolism and excretion of one or more investigational medicinal product(s) with the object of ascertaining its (their) safety and/or efficacy;